Published research on Survodutide: record counts, recent publications, reviews and registered studies, pulled from PubMed and ClinicalTrials.gov. Part of metabolic research.
Ask TinaTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Registered studies by status: 4 recruiting, 3 active not recruiting, 18 completed.
Number of PubMed records mentioning Survodutide, 2016 to 2026 (2026 is year to date).
Most recently started of 29 ClinicalTrials.gov entries.
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900 · Not Yet Recruiting · Phase 3 · started 2026-11-07SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050 · Not Yet Recruiting · Phase 3 · started 2026-10-31ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063 · Not Yet Recruiting · Phase 3 · started 2026-10-23A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityNCT07768813 · Recruiting · Phase 1 · started 2026-09-02A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · Recruiting · Phase 3 · started 2026-08-24A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07407348 · Active Not Recruiting · Phase 1 · started 2026-03-11A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorNCT07413913 · Completed · Phase 1 · started 2026-03-03Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 · Not Yet Recruiting · Phase 2 · started 2026-03-02A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07221591 · Completed · Phase 1 · started 2025-11-05A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the BodyNCT07071974 · Completed · Phase 1 · started 2025-07-28A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284 · Active Not Recruiting · Phase 1 · started 2025-03-26A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyNCT06772532 · Completed · Phase 1 · started 2025-02-10Positive coverage and opinions: this section collects news and commentary that read favorably.
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesBoehringer Ingelheim (via GlobeNewswire) · Oct 1, 2026Primary data for your own interpretation: published studies and regulator documents. No publisher opinion pieces.
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.J Chromatogr A · 2026 Jul 21 · Tong LH et al. · PubMedGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutr Clin Pract · 2026 Oct · Singhani V et al. · PubMedEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes Obes Metab · 2026 Sep 29 · Amjad MM et al. · PubMedRecent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes Metab Syndr Obes · 2026 Sep 2 · Puspitasari IM et al. · PubMedPharmacological management of obesity: Current landscape and emerging therapies.Indian J Pharmacol · 2026 Sep 2 · Atal S et al. · PubMedEfficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.Cureus · 2026 Jun 29 · Santos Solis R et al. · PubMedObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabol Open · 2026 Mar 23 · Lempesis IG et al. · PubMedEfficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.J Transl Med · 2026 May 26 · Sun XY et al. · PubMedComparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.Endocrinol Diabetes Metab · 2026 Mar · Abulehia A et al. · PubMedEfficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.J Hepatol · 2024 Jun 8 · Lawitz EJ et al. · PubMedAsk Tina for links to further coverageTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.